Expression and clinical relevance of PD-L1 on circulating B cells in patients with systemic lupus erythematosus
10.3969/j.issn.1673-4130.2019.04.017
- VernacularTitle:系统性红斑狼疮患者外周血B细胞中PD-L1的表达及临床意义
- Author:
Yan LU
1
;
Xiaosheng QIN
Author Information
1. 来宾市兴宾区人民医院检验科
- Keywords:
systemic lupus erythematosus;
programmed death ligand 1;
renal injury;
disease activity
- From:
International Journal of Laboratory Medicine
2019;40(4):445-447
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between the levels of programmed death ligand 1 (PD-L1) on circulating B cells and disease severity as well as renal injury of patients with systemic lupus erythematosus (SLE) .Methods 50patients with SLE were enrolled from May 2015to May 2017, and 20healthy individuals were enrolled as the control group.All patients were scored for their disease severity and renal injury.The expression of PD-L1on circulating B cells were evaluated by flow cytometery.Results In the group of patients with active SLE, the percentage of CD19+in B cells was (11.35±3.65) ％and the percentage of in CD19+B cells was (2.47±0.89) ％, both of which were significantly higher than that in the group of patients with non-active SLE and control group (P<0.05) .In addition, patients with SLE were divided into lower group and higher group according to the median percentage of CD19+and CD19+/PD-L1Bcells.The incidence of kidney lesion was robustly increased in the high group, and CD19+/PD-L1Bcells, LNⅣwere independent risk factors of renal insufficiency in lupus nephritis.Conclusion The level of peripheral CD19+/PD-L1in SLE patients increased significantly and was closely related to the activity degree and renal injury of the disease, which was an independent risk factor for renal insufficiency in patients.
